PPC Group, founded in 1997, is a China Centric Asia-Pacific clinical CRO company. Headquartered in Shanghai, PPC Group also set up branch companies and offices in Taipei, Xuzhou, Beijing, Shenyang, Seoul and Tokyo.
PPC Group provides professional services for clinical studies to pharmaceutical and biotechnology companies and offers clinical and laboratory services in China, Taiwan, Korea and Japan. Since 1997, PPC has completed over 2000 phase I trials as well as over 500 innovative phase II-IV trials, covering all 24 therapeutic areas. Moreover, PPC’s Phase I Units and Bioanalytical Labs have been audited more than 30 times by numerous regulatory authorities, including FDA, NMPA, TFDA, PMDA, EMA, NPRA and etc.
To fulfill harmonized bioequivalence standard for phase I clinical site, PPC group has set up a phase I center in Taipei MacKay Memorial Hospital in 2012; and co-found a phase I center with Xuzhou medical hospital in early 2017. Combining the strengths of Xuzhou Medical University, PPC has established strong early phase drug development especially in the bioavailability and bioequivalence research field over the past two decades. In 2018, PPC had set up 2 more dedicated Phase I Units in Xuzhou Central Hospital and Hubei Huangshi Central Hospital.